Takeda

This study tests a dengue vaccine (TDV) in children aged 6 to 21 months. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive two shots three months apart and are monitored for side effects and antibody levels.

This phase 3 trial is testing a dengue vaccine (TDV) in 800 adults aged 45 to 79, including those with diabetes, high blood pressure, or kidney disease. Participants will receive two shots three months apart. The study aims to check for side effects and measure the immune respons…

This study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…

This study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…

This study is testing the drug vedolizumab (Entyvio) in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first receive the drug through an IV for 6 weeks, then switch to injections under the skin for the rest of the year. The main goal is to …

This phase 2 trial is testing whether TAK-755, a lab-made protein that helps break up blood clots, is safe and effective for people who have had an acute ischemic stroke. About 222 adults aged 18 to 80 will receive either TAK-755 or a placebo, along with standard stroke care, and…

This Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…

This study tests whether combining two drugs—vedolizumab and tofacitinib—can quickly bring moderate to severe ulcerative colitis under control. About 65 adults will receive both drugs for 8 weeks, and those who respond will continue on vedolizumab alone for nearly a year. The goa…

This study is testing whether combining two different biologic drugs can better control moderate to severe Crohn's disease. One hundred adults will first receive either vedolizumab plus adalimumab or vedolizumab plus ustekinumab. Those who respond well will then switch to vedoliz…

This Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …

This Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…

This Phase 3 trial tests whether giving immune globulin (IGI) regularly can prevent serious infections in adults with multiple myeloma who are receiving a bispecific antibody therapy. About 183 participants will be randomly assigned to get IGI right away for 12 months or only aft…

This Phase 3 trial tests whether mezagitamab, given as a shot under the skin, can safely keep platelet counts stable in adults with chronic ITP. ITP is a condition where the immune system destroys platelets, leading to easy bruising and bleeding. The study will compare mezagitama…

This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection did not improve with standard treatments. Participants take Maribavir tablets as part of their regular care, and doctors monitor side effects and whether the virus clears from the blood for …

This study tracks 25 people in Japan with acquired hemophilia A who receive the drug OBIZER to control bleeding. Researchers will watch for side effects and check if the drug helps stop bleeding episodes. The study does not change how doctors treat patients—it simply collects rea…

This trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…

This study tests a drug called TAK-226 (Elritercept) in 27 Japanese adults with lower-risk myelodysplastic syndromes (MDS) who need regular blood transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. Participants will receive inj…

This Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

This study tests whether vedolizumab (Entyvio) can improve symptoms and reduce inflammation in children with chronic pouchitis, a condition where an internal pouch becomes inflamed after bowel surgery. About 30 children will receive up to 12 infusions over 82 weeks. The main goal…

This study looks at how children and teenagers with moderate to severe ulcerative colitis or Crohn's disease process a drug called vedolizumab when given as a shot under the skin. About 70 participants who already responded to vedolizumab given through a vein will receive the sho…

This study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…

This study looks at how well a medicine called Ceprotin (TAK-662) works and how safe it is for people with congenital protein C deficiency, a rare inherited condition that raises the risk of dangerous blood clots. Participants receive the medicine through an IV as part of their u…

This Phase 3 trial compares elritercept to epoetin alfa in 300 adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who need red blood cell transfusions. The main goal is to see if elritercept can help patients go without transfusions for at least 12 weeks while …

This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking…

This phase 3 trial tests whether zasocitinib, an oral medication, can safely and effectively treat moderate-to-severe plaque psoriasis in children and teens aged 4 to 17. The study involves 110 participants and lasts up to 4 years. In the first part, some receive the drug and oth…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This expanded access program provides TAK-881, a subcutaneous immunoglobulin treatment, to people with primary immunodeficiency diseases (PIDD) who completed a prior study and continue to benefit from the therapy. Participants receive regular infusions under the skin using a spec…

This study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the …

This phase 4 trial is testing the safety and effectiveness of the oral drug fruquintinib in 78 adults from minority groups (Black/African American and Hispanic/Latino) with advanced colorectal cancer that hasn't responded to other treatments. The main focus is on how often high b…

This study tests an oral drug called TAK-279 (Zasocitinib) in 268 adults with moderate-to-severe Crohn's disease who haven't responded well to other treatments. Participants take one of three doses or a placebo daily for 12 weeks to see if it reduces gut inflammation and ulcers, …

This phase 3 trial tests a drug called teduglutide in 13 Chinese adults with short bowel syndrome who rely on IV nutrition. Participants get a daily injection for 24 weeks to see if it reduces their need for IV support. The study also checks safety and how the body processes the …

This study looks at the long-term safety of a drug called vedolizumab given as a shot under the skin to children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who did well on the drug in an earlier study will keep getting it, while those who didn…

This Phase 3 trial tests TAK-330, a drug designed to reverse the effects of common blood thinners (Factor Xa inhibitors) in patients who need urgent surgery. About 440 adults will be randomly assigned to receive TAK-330 or standard care before their procedure. The main goal is to…

This study follows about 10 adults and children (12 years and older) in Argentina who have a CMV infection after an organ transplant that did not get better with standard treatments. Researchers will track how well maribavir works and what side effects occur during routine care. …

This study is checking how well the drug brentuximab vedotin works for adults with Hodgkin lymphoma who have had a stem cell transplant. Researchers will track 70 participants for about 2 years to see if the drug helps prevent the cancer from coming back. It is an observational s…

This study tests whether giving two drugs together (vedolizumab and upadacitinib) for 12 weeks works better than vedolizumab alone to reduce bowel inflammation and ulcers in adults with moderate to severe Crohn's disease. About 396 participants will receive the combo or a placebo…

This study tests a drug called vonicog alfa to prevent bleeding in 24 children with severe von Willebrand disease, a condition that causes easy bruising and heavy bleeding. Participants receive the drug regularly for 12 months to see if it reduces bleeding episodes compared to th…

This study tests a drug called maribavir for children and teens who have a CMV infection after a stem cell or organ transplant. About 80 participants will take the drug for 8 weeks and be followed for 12 more weeks. The goal is to find the safest dose and see how well it controls…

This study tests the long-term safety of an oral drug called zasocitinib (TAK-279) in adults with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to the drug in earlier studies can continue treatment for up to 3 years. The main goal is to see …

This study is checking how safe OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden and severe bleeding. Researchers will look at medical records and track side effects in about 9 people. The goal is to see how well the drug controls bleeding in e…

This phase 3 trial tests elritercept, a drug given as a shot every 4 weeks, to see if it can help adults with a bone marrow disease called MDS go without red blood cell transfusions for at least 8 weeks. About 225 participants with very low- to intermediate-risk MDS who need regu…

This study tests an experimental drug called fazirsiran in 160 adults with Alpha-1 antitrypsin deficiency who have moderate to severe liver scarring. The goal is to see if fazirsiran can reduce fibrosis and slow disease progression compared to a placebo. Participants will receive…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This study is for children with ulcerative colitis or Crohn's disease who already completed a previous vedolizumab trial. It aims to see how safe the drug is over a longer period. About 240 kids will receive vedolizumab infusions or be observed without treatment. Researchers will…

This study tests a medicine called vedolizumab in children and teens with moderate to severe Crohn's disease. The goal is to see if the drug can reduce inflammation and keep symptoms under control over the long term. Participants first receive three infusions over six weeks, then…

This Phase 2 study is testing TAK-411, a specially modified immune globulin, in 36 adults with CIDP, an autoimmune disease that attacks nerve insulation and causes muscle weakness. The main goal is to see if TAK-411 improves physical function over 24 weeks compared to historical …

This study tracks side effects of the drug ADCETRIS (brentuximab vedotin) when given with standard chemotherapy to children and teenagers with untreated CD30-positive Hodgkin lymphoma. The main focus is on serious side effects like low blood counts, nerve damage, and lung problem…

This program offers continued treatment with idursulfase-IT (TAK-609), given directly into the spinal fluid, plus standard intravenous Elaprase, for children and adults with Hunter syndrome who have cognitive impairment. It is only open to people who completed earlier studies of …

This study tracks side effects, especially lung problems, in 500 Japanese people with a specific type of non-small cell lung cancer taking Brigatinib. Doctors will monitor participants for 1 year as they receive standard treatment. The goal is to better understand the drug's safe…

This study looks at whether a drug called teduglutide can help children aged 1 to 17 with short bowel syndrome reduce the amount of nutrition they get through a vein. The study will review past medical records and collect new data from about 12 children in China. The goal is to s…

This study is checking the long-term safety of a drug called TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier trials. Participants will continue taking TAK-861 tablets, and researchers will monitor for side effects. The goal is to see if the drug …

This study tests a medicine called fazirsiran for people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug works by reducing the buildup of an abnormal protein in the liver that causes damage. About 50 participants will receive either fazirsiran o…

This study tests a new drug called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful, pus-filled bumps. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for 8 more month…

This early-stage study tests whether the experimental drug TAK-781 is safe and tolerable in healthy volunteers and in people with primary sclerosing cholangitis (PSC), a chronic liver disease. The study also looks at how the body processes the drug. About 134 participants will be…

This study tests a drug called maribavir in Chinese adults who had a stem cell or organ transplant and have a CMV infection that did not get better with standard treatments. The main goal is to see if maribavir is safe and well-tolerated. Researchers will also check if the drug c…

This program provides children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through a vein, after they finish a related study. It is for those who still benefit from the treatment and have no good …

This study in Japan looks at how safe and effective Vonvendi (rVWF) is for children under 18 with Von Willebrand Disease, a bleeding disorder. About 13 kids will receive the drug as part of their normal care for bleeding episodes or before surgery. Researchers will monitor side e…

This phase 4 study is testing the safety and effectiveness of brentuximab vedotin (Adcetris) combined with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) in 124 Indian adults with untreated stage 3 or 4 classical Hodgkin lymphoma. Participants will receive the …

This study tests a drug called elritercept (KER-050) in 160 adults with a bone marrow condition called myelodysplastic syndromes (MDS) who have anemia. The main goals are to check the drug's safety and how well people tolerate different doses. Researchers will also see if it help…

This study tests a new drug called elritercept (KER-050) for people with myelofibrosis, a rare bone marrow disorder. The drug is given alone or with the standard treatment ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. About 13…

This phase 3 trial is testing whether a new, more concentrated antibody treatment (TAK-881) works similarly to the current standard (HYQVIA) for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). About 59 participants who already receive antibody infusi…

This study tests a drug called VONVENDI (recombinant von Willebrand factor) in 20 Chinese adults with von Willebrand disease, a bleeding disorder. The goal is to see if it is safe and helps control bleeding during surgery or dental procedures, sometimes combined with another drug…

This study follows 200 Chinese children and adults with Fabry disease who are receiving routine treatment with Replagal (agalsidase alfa). The goal is to see how the therapy affects heart and kidney function over time, as well as quality of life and safety. Participants continue …

This study follows 30 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will use questionnaires and medical records to understand why patients chose to switch, how satisfied they are, and how the treatment …

This study follows 168 adults in South Korea who have had a transplant and developed a CMV infection that didn't respond to other treatments. They will take LIVTENCITY (Maribavir) as part of routine care, and researchers will track side effects and how well the drug clears the vi…

This study follows 275 Crohn's disease patients in Japan who receive darvadstrocel, a stem cell injection, for complex anal fistulas. Researchers will monitor side effects and whether fistulas close over 36 months. The goal is to see if this treatment is safe and works in real-wo…

This phase 3 trial tests the drug vedolizumab in 408 adults in China with moderate-to-severe Crohn's disease. Participants receive IV infusions of vedolizumab or a placebo over several weeks. The goal is to see if vedolizumab can reduce symptoms like abdominal pain and diarrhea, …

This study monitors 40 people in Japan with congenital thrombotic thrombocytopenic purpura (cTTP) who are receiving ADZYNMA (recombinant ADAMTS13) as part of their routine care. Researchers will track side effects and check if the drug improves platelet counts and ADAMTS13 activi…

This program provides continued compassionate access to recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who completed a prior study and are benefiting from treatment. Participants must have no comparable alternative therapy avai…

This study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part.…

This study tests whether a daily medication called vortioxetine can safely reduce depression symptoms in Japanese teenagers aged 12 to 17 with major depressive disorder. About 180 participants will receive either the drug or a placebo for 14 weeks, with follow-up for 4 more weeks…

This study tests a new drug called TAK-360 for people with narcolepsy type 2, a condition that causes severe daytime sleepiness. The drug acts like a natural brain chemical (orexin) that helps keep people awake. About 88 adults will receive either TAK-360 or a placebo to see if t…

This Phase 2 trial tests TAK-360, a drug that mimics the brain chemical orexin, in 96 adults with idiopathic hypersomnia (IH). IH causes severe daytime sleepiness and trouble waking up, even after long sleep. Participants will receive either TAK-360 or a placebo to see if the dru…

This study tests a new drug, TAK-360, for adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). About 92 participants will receive either TAK-360 or a placebo to see if the drug is safe and well-tolerated. Participant…

This study looks back at medical records of about 100 people in Japan with primary immunodeficiency who received Cuvitru. The goal is to track serious side effects like allergic reactions, blood clots, and meningitis. No new treatment is given—researchers are simply analyzing exi…

This study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease progresses without any special treatment. Researchers will track changes in liver scarring, symptoms, and overall health using medical records and yearly ques…

This study looks at the real-world safety of Adzynma, a lab-made protein, in people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder. Researchers will review medical records of about 50 children and adults to see how many develop allergi…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. No treatment o…

This study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who took Takhzyro (lanadelumab) to prevent attacks. Researchers want to see if the drug reduces HAE activity and improves quality of life after 6 to 12 months. No new treatments…

This study looks at how much of the constipation medicine prucalopride passes into breast milk. Researchers will collect milk samples from 12 women over 24 hours and track their babies' growth and any side effects for one year. The goal is to understand infant exposure, not to tr…

This study looks at whether the dengue vaccine (TDV) helps prevent hospital stays due to dengue in children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for 3 years, comparing those who got the vaccine with those who did not. The goa…

This study tracks side effects and safety of the cancer drug Fruzaqla (fruquintinib) in 600 adults with colorectal cancer in South Korea. Participants take the drug as prescribed by their doctor. The goal is to see how often side effects occur in everyday use, not to test a new t…

This study is monitoring 50 children in Japan with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC) who are taking the drug Livmarli (maralixibat). Researchers are using a national registry to track how many children develop liver problems and how …

This observational study follows 75 multiple myeloma patients with secondary immunodeficiency who are receiving HyQvia as part of their routine care. Researchers will collect data on infusion details like dose, rate, and site, as well as any reasons for stopping or switching trea…

This study uses a survey to see how well patients and doctors understand the risks and required checkups for the drug GATTEX, used to treat Short Bowel Syndrome. About 600 people—adults who have taken GATTEX in the last 60 days and their healthcare providers—will answer true/fals…

This study reviews medical records of 10 adult transplant patients who have a hard-to-treat CMV infection along with severe kidney disease or kidney failure. Researchers want to see how safe the drug maribavir is for these patients. No new treatments or procedures are given; the …

This study is for adults in South Korea with ulcerative colitis or Crohn's disease who are already taking vedolizumab injections. Researchers will look at medical records to track side effects and how well the treatment works. No new medicine or treatment is given—this is just an…